{"id":"W2950848761","doi":"10.1016/j.joco.2019.05.002","title":"Ocular adverse events with immune checkpoint inhibitors","year":2019,"lang":"en","type":"article","venue":"Journal of Current Ophthalmology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"Foundation for Anesthesia Education and Research","keywords":"Medicine; Nivolumab; Pembrolizumab; Adverse effect; Ipilimumab; Atezolizumab; Uveitis; Durvalumab; Odds ratio; Adverse Event Reporting System; Internal medicine; Immunology; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00363689,0.0004806757,0.0005712686,0.001972978,0.0002664898,0.0007258118,0.0002801201,0.0002874736,0.002327864],"category_scores_gemma":[0.0109561,0.0001316791,0.002407026,0.001833759,0.0003162243,0.0004620569,0.0009876075,0.0007261878,0.0002068366],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007735195,"about_ca_system_score_gemma":0.0005639935,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001625122,"about_ca_topic_score_gemma":0.002169731,"domain_scores_codex":[0.9930032,0.001677599,0.00172788,0.0009460213,0.002292322,0.0003529824],"domain_scores_gemma":[0.9748753,0.003494435,0.01971528,0.0004773257,0.001033642,0.0004040786],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0009952118,0.0000524496,0.9675468,0.0008624035,0.001631102,0.000190278,0.00002896164,0.0003891712,0.0004336524,0.000132307,0.0008083318,0.02692945],"study_design_scores_gemma":[0.00008693393,0.0007003075,0.9872426,0.0004032055,0.001056116,0.003624442,0.0000816488,0.0006937862,0.0008556301,0.0001895266,0.005048267,0.00001757208],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9261012,0.04656975,0.003459107,0.0005727784,0.0001466646,0.0006300742,0.01138287,0.0001361737,0.01100141],"genre_scores_gemma":[0.9910949,0.004375399,0.001270574,0.000273493,0.0001236726,0.0001268584,0.00226372,0.000009918033,0.000461345],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00363689,"threshold_uncertainty_score":0.019234,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02193169367885373,"score_gpt":0.3123402495225097,"score_spread":0.2904085558436559,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}